ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 4.460
+0.120 (2.76%)
At close: Mar 27, 2026
HKG:1541 Revenue
In the year 2025, ImmuneOnco Biopharmaceuticals (Shanghai) had annual revenue of 154.29M CNY with 93.99% growth. ImmuneOnco Biopharmaceuticals (Shanghai) had revenue of 44.01M in the half year ending June 30, 2025, with 3,815.84% growth.
Revenue
154.29M CNY
Revenue Growth
+93.99%
P/S Ratio
11.21
Revenue / Employee
791.25K CNY
Employees
195
Market Cap
1.92B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.29M | 74.76M | 93.99% |
| Dec 31, 2024 | 79.54M | 71.84M | 933.61% |
| Dec 31, 2023 | 7.70M | 2.01M | 35.24% |
| Dec 31, 2022 | 5.69M | -8.12M | -58.79% |
| Dec 31, 2021 | 13.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| Mabpharm | 464.53M |
| Cutia Therapeutics | 374.07M |
| CANbridge Pharmaceuticals | 68.55M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| Zhaoke Ophthalmology | 38.74M |
| Kintor Pharmaceutical | 12.04M |